Watch: the CureRays® explainer series
Prefer to read? The full guide below is complete on its own, with tables you can revisit any time.
What is synovial sarcoma?
Synovial sarcoma is a soft-tissue sarcoma — a cancer of the body's connective tissues — that tends to occur in adolescents and younger adults, an age group in which most cancers are uncommon. Despite its name, it does not actually come from the synovium (the lining of joints); the name reflects how the cells looked to early pathologists, but the tumor can arise anywhere in the soft tissues. It most often appears near a large joint, especially around the knee, thigh, or other parts of the arms and legs, as a deep, slowly growing mass that may be present for a long time and is sometimes mistaken for a benign cyst or a sports injury. Because it can grow quietly, a deep soft-tissue lump that persists, grows, or is larger than a few centimeters — particularly in a young person — should be imaged and biopsied at a sarcoma center rather than assumed to be harmless. Synovial sarcoma is defined at the molecular level by a characteristic gene fusion (an SS18 rearrangement), and finding that fusion confirms the diagnosis. It is generally considered a higher-grade, aggressive cancer that can spread, most often to the lungs, sometimes years after the original tumor — which is why long-term follow-up is important. Treatment combines complete surgical removal of the tumor with radiation to treat the microscopic disease that extends beyond the visible mass, so the limb can be preserved and the chance of local recurrence kept low. Chemotherapy plays a larger role in synovial sarcoma than in many other adult soft-tissue sarcomas, because this tumor is relatively chemotherapy-sensitive and tends to affect younger, otherwise-healthy patients who can tolerate it; it is considered especially for larger, higher-risk tumors and for disease that has spread.
The main types
Doctors group synovial sarcoma by where it starts and how it behaves:
| Type | What it means, simply |
|---|---|
| Monophasic synovial sarcoma | The most common pattern under the microscope, made of a single spindle-cell type; behaves and is treated like the others — diagnosis rests on finding the characteristic gene fusion. |
| Biphasic synovial sarcoma | Shows two cell patterns (spindle cells plus gland-like areas); recognized on pathology, with the same treatment approach combining surgery, radiation, and chemotherapy as appropriate. |
| Poorly differentiated synovial sarcoma | A more aggressive-appearing form with a higher risk of spread; treated similarly but with stronger consideration of chemotherapy because of the elevated risk. |
| Extremity (near-joint) synovial sarcoma | The typical presentation — a deep mass near a joint in an arm or leg; treated with limb-sparing surgery and radiation, with excellent rates of keeping the limb. |
Staging, in plain terms
Synovial sarcoma is staged with the soft-tissue sarcoma TNM system, with the grade carrying particular weight. Grade describes how aggressive the cells look and how quickly the tumor is likely to grow and spread; synovial sarcoma is generally treated as a higher-grade cancer. The T category reflects the size and depth of the tumor — larger and deeper tumors are higher T and carry more risk — while the N category notes lymph-node involvement, which is uncommon, and the M category notes distant spread, which for synovial sarcoma most often means the lungs. Because it spreads through the bloodstream to the lungs rather than reliably through lymph nodes, a CT scan of the chest is a standard part of the work-up and of follow-up, and follow-up continues for many years because spread can appear late. The diagnosis itself is confirmed not by stage but by molecular testing: synovial sarcoma carries a characteristic SS18 gene fusion, and identifying it distinguishes this tumor from look-alike sarcomas and guides treatment. In practice, the questions that shape care are how big and deep the tumor is, what its grade is, where it sits relative to the joint, nerves, and blood vessels (which affects limb preservation), and whether it has spread. Those answers determine the combination and order of surgery, radiation, and chemotherapy. Because patients are often young and the tumor is relatively chemotherapy-sensitive, chemotherapy is weighed more heavily here than in many other adult sarcomas.
| Soft-tissue sarcoma TNM with grade — tumor size and depth (T), lymph nodes (N), distant spread (M), and grade; molecular confirmation of the SS18 gene fusion establishes the diagnosis | What it generally means |
|---|---|
| Localized, small | A tumor confined to its site and relatively small; treated with limb-sparing surgery and radiation, with a good chance of cure. |
| Localized, larger high-grade | A bigger, deep tumor still confined locally; treated with surgery and radiation, with chemotherapy considered to lower the risk of later spread. |
| Locally advanced | A tumor closely involving nerves, major vessels, or a joint; treated with radiation and surgery planned together, often with chemotherapy, to remove it while preserving the limb when possible. |
| Metastatic (usually lungs) | Cancer that has spread, most often to the lungs; treated with chemotherapy and other systemic therapy, with surgery or focused radiation for a limited number of deposits. |
The standard of care
Synovial Sarcoma is almost always treated by a team that may include a surgeon, a medical oncologist, and a radiation oncologist, combining therapies for the best result. The usual building blocks are:
Limb-sparing surgery
Removing the tumor with a margin of healthy tissue while preserving the limb and as much function as possible — the central treatment, and the goal in the great majority of extremity cases.
Radiation therapy (before or after surgery)
Given alongside surgery to treat the microscopic disease beyond the visible tumor; it allows smaller operations that keep the limb and substantially lowers the chance of local recurrence.
Chemotherapy
Used more here than in many adult sarcomas because synovial sarcoma is relatively chemotherapy-sensitive and patients are often young; considered for larger, higher-risk tumors and used for disease that has spread.
Molecular diagnosis and chest imaging
Confirming the SS18 gene fusion establishes the diagnosis, and CT scans of the chest stage the lungs and guide long-term follow-up, since spread can appear years later.
Sarcoma specialty center care
Treatment at a center with a dedicated sarcoma team — surgery, radiation, and medical oncology together — gives the best chance of cure and limb preservation, especially important for younger patients.
How radiation treatment works
Radiation therapy treats synovial sarcoma by delivering focused beams of energy that damage the DNA inside tumor cells so they can no longer grow and divide. As with other soft-tissue sarcomas, the reason radiation pairs so naturally with surgery comes from how the tumor grows: rather than staying within the firm, visible mass, it pushes microscopic fingers of tumor into the surrounding tissue beyond what can be seen or felt. If a surgeon removed only the visible tumor, those microscopic extensions could be left behind and seed a recurrence. Radiation treats a wider zone around the tumor, sterilizing the microscopic disease so the limb can be preserved and the cancer is far less likely to come back locally. Because synovial sarcoma so often arises near a joint in a young person with many active years ahead, preserving the limb and its function is a central goal, and combining a smaller operation with radiation achieves local control as good as more radical surgery once did. Radiation can be given before or after surgery: beforehand it uses a smaller treatment area and a lower dose and is associated with better long-term limb function, though it requires extra attention to wound healing; afterward it treats the tumor bed at a higher dose over a larger area. Modern techniques such as intensity-modulated radiation shape the dose tightly around the target to spare the surrounding muscle, bone, and joint — an especially important consideration in young patients who will live with the treated limb for decades. Radiation also has a role beyond the original site: when synovial sarcoma spreads to a limited number of spots in the lungs, focused high-dose radiation (stereotactic body radiation) can ablate those deposits and provide durable control without surgery. Throughout, radiation works alongside surgery and, more often than in many adult sarcomas, chemotherapy, because this tumor is relatively chemotherapy-sensitive and tends to affect younger, otherwise-healthy patients.
The main ways radiation is delivered for synovial sarcoma:
Preoperative (neoadjuvant) radiation
Radiation given before surgery treats the rim of microscopic disease using a smaller field and lower dose, which can make a limb-sparing operation safer and is associated with less long-term stiffness, at the cost of more wound-healing care.
Postoperative (adjuvant) radiation
Radiation to the tumor bed after surgery, used when preoperative radiation wasn't given, treats microscopic disease left behind and lowers the chance of local recurrence, at a higher dose over a larger area.
Intensity-modulated radiation (IMRT)
Shaping the beams tightly around the target spares surrounding muscle, bone, and the nearby joint, helping preserve limb function — particularly valuable in young patients with many active years ahead.
Stereotactic body radiation (SBRT) for metastases
Focused, high-dose radiation can ablate a limited number of lung metastases, offering durable control of oligometastatic disease without surgery.
Latest studies shaping care
Care keeps improving — often toward getting the same excellent results with less burden on patients. A few developments:
Radiation plus limb-sparing surgery preserves limbs and controls disease: Landmark trials established that combining radiation with limb-sparing surgery gives local control equal to amputation for extremity soft-tissue sarcomas, allowing most patients — including young synovial sarcoma patients — to keep a functional limb.[1]
Limb-sparing surgery plus radiotherapy sarcoma trials
Chemotherapy's role in synovial sarcoma: Because synovial sarcoma is relatively chemotherapy-sensitive and often affects younger patients, studies support adding chemotherapy for larger, higher-risk tumors and using it for metastatic disease, a more prominent role than in many other adult sarcomas.[2]
Synovial sarcoma chemotherapy studies
Cell-based therapy targeting synovial sarcoma: Synovial sarcoma's distinctive molecular markers have made it a leading target for engineered T-cell (TCR) therapies, with newer treatments showing responses in advanced disease and opening a new avenue beyond chemotherapy.[3]
Engineered T-cell therapy trials in synovial sarcoma
Common questions
I'm young and healthy — why did I get this cancer? Synovial sarcoma is one of the few cancers that disproportionately affects adolescents and younger adults, and in nearly all cases it is not inherited and not caused by anything you did. It arises from a specific genetic change — an SS18 gene fusion — that occurs in a cell by chance and is found in the tumor, not in the rest of your body. There is rarely an identifiable cause or anything that could have prevented it. What matters now is getting treatment at a sarcoma center, where the combination of surgery, radiation, and chemotherapy is tailored to give the best chance of cure while preserving your limb and function.
Why is chemotherapy used more for synovial sarcoma than for some other sarcomas? Two reasons. First, synovial sarcoma is relatively chemotherapy-sensitive compared with many other adult soft-tissue sarcomas, so chemotherapy is more likely to help. Second, it tends to affect younger, otherwise-healthy people who can tolerate chemotherapy well. For these reasons, chemotherapy is weighed more heavily here — considered especially for larger or higher-risk tumors and used for disease that has spread — alongside the surgery and radiation that control the tumor where it started.
Why do I need follow-up for so many years? Synovial sarcoma can spread to the lungs, and that spread sometimes appears years after the original tumor was treated. Because of this, follow-up — including periodic imaging of the chest — continues for a long time, so that any spread can be found early when it is most treatable. If a limited number of lung deposits appear, they can often be removed surgically or treated with focused, high-dose radiation. Staying on schedule with follow-up visits is an important part of long-term care.
References
Numbered sources for the studies cited above. Links open the primary publication on PubMed or the publisher’s site.